The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
Confirm
Session Speakers:
Incorporation of Platform Based Approaches and Prior Knowledge Leveraging Into the Recently Revised ICH Q5A (R2) Guideline
Kathryn King, CDER, FDA
Power of Platform to Accelerate Therapies Beyond a Pandemic
Ronan Kelly, Eli Lilly and Company
Leveraging Platforms to Accelerate ADC Formulation and Drug Product Development
Karen Rutherford, Pfizer Inc.
Continuous Platform Improvement to Propel Drug Substance Development,
Heather Nunn, Amgen Inc.